Related Experiment Video
Updated: May 27, 2026
09:13
Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
Published on: November 1, 2011
Rotarix®: vaccine performance 6 years postlicensure.
Miguel O'Ryan1, Yalda Lucero, Alexandre C Linhares
1Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile. moryan@med.uchile.cl
Expert Review of Vaccines
|November 17, 2011
Summary
Rotarix, a rotavirus vaccine, shows continued global impact and safety in post-licensure studies. This review details its effectiveness, especially against G2P[4] strains, in diverse immunization programs.
Area of Science:
- Vaccinology
- Public Health
- Infectious Diseases
Background:
- Rotarix (®) vaccine licensed in 2004 for rotavirus prevention.
- Previous review covered pre-licensure data and cost-effectiveness.
- As of Sept 2011, licensed in 123 countries, with 27 national program inclusions.
Purpose of the Study:
- Provide updated insights on Rotarix vaccine post-2004 licensure.
- Summarize post-licensure vaccine impact and safety data.
- Analyze protection specifically against rotavirus G2P[4] strain.
Main Methods:
- Review of post-licensure effectiveness and observational studies.
- Analysis of real-world data on vaccine performance.
- Focus on data gathered over a 6-year post-licensure period.
Main Results:
- Rotarix has demonstrated significant global impact in diverse settings.
- Post-licensure studies confirm vaccine safety profile.
- Evidence of protection against rotavirus G2P[4] strains is presented.
Conclusions:
- Rotarix continues to be an effective tool in reducing rotavirus disease burden globally.
- Real-world data supports the established safety and efficacy of Rotarix.
- Further understanding of Rotarix performance against specific strains like G2P[4] is crucial.
Related Concept Videos
01:51Vaccinations
Overview
01:21Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:23Immunological Memory
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...
01:20Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...